Back to top
more

Enanta Pharmaceuticals (ENTA)

(Delayed Data from NSDQ)

$13.23 USD

13.23
154,132

-0.77 (-5.50%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $13.22 -0.01 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -33.90% and 20.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The Zacks Analyst Blog Highlights Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World

Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World are included in this Analyst Blog.

Sweta Killa headshot

5 Secret Santa Stocks to Pop Surprise Returns

Enanta Pharmaceuticals (ENTA), OneConnect Financial. (OCFT), KNOT Offshore (KNOP), Hippo Holdings (HIPO) and H World Group (HTHT) could surprise investors with big returns this Christmas.

Wall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals (ENTA): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 108.1% in Enanta Pharmaceuticals (ENTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Enanta Pharmaceuticals (ENTA)? Wall Street Analysts Think 88.23%

The mean of analysts' price targets for Enanta Pharmaceuticals (ENTA) points to an 88.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alpine Immune Sciences, Inc. (ALPN) Surges 8.9%: Is This an Indication of Further Gains?

Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 21.85% and 19.01%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Enanta Pharmaceuticals (ENTA) Stock?

Investors need to pay close attention to Enanta Pharmaceuticals (ENTA) stock based on the movements in the options market lately.

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 6.28% and 9.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 8.55% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 7.30% and 9.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Misses Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of 0% and 54.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates

MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -240% and 91.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -12.50% and 3.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Enanta Pharmaceuticals (ENTA) Q3 Earnings Expected to Decline

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Enanta Pharmaceuticals (ENTA) Stock Jumps 10.1%: Will It Continue to Soar?

Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops

While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.